Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company's multiple sclerosis products.
| Ticker |
Sentiment |
Impact |
|
ESALF
|
Somewhat Bullish
|
11 %
|
|
BIIB
|
Bullish
|
52 %
|
